new solution for breast cancer


new solution for breast cancer

Early diagnosis is important

early diagnosis most powerful way to give patients the best possible chance of surviving the disease

Our Science

Our core technology is to detect

breast cancer using targeted and specific vesicles

facilitated by radionuclide radiotracers

Our core technology is to detect
breast cancer using targeted and specific vesicles
facilitated by radionuclide radiotracers

Exosome-based diagnostics and therapeutics

Exosomes are naturally occurring biological nanovesicles (30–200 nm) released by normal cells such as macrophages , mesenchymal stem cells , natural killer cells , and red blood cells.
Exosomes, nanometer-sized lipid bilayer-enclosed vesicles carry myriad donor cell-derived bioactive molecules such as proteins, lipids, and RNAs (including microRNA and lncRNA) and can deliver them to both nearby and distant recipient cells.
Due to these characteristics, exosomes have attracted great interest in cancer treatment (especially serving as a biological carrier for some drugs, microRNA, lncRNA, inhibitors, and antibodies (RBCs) , as well as tumor cells.

Precise and personalized radiology and nuclear medicine are in need of a new, biological contrast media and radionuclide. This inventive strategy is progressing due to the developing of contrast agents and radionuclides based on exosomes. The compatibility of exosomes With existing imaging modalities can accelerate incorporating these methods into clinical practice. Besides, a new generation of contrast media and radionuclides based on exosomes provides an opportunity to develop novel approaches in cancer diagnosis

Our Technology

We are produced by HEK 293 cells. Exosomes are targeted against HER2 receptors by genetic manipulation. Targeted exosomes are labeled by gamma emitting radionuclides to detect tumors even in deep organs by PET/SPECT imaging.

Our nanosized based detection system called exosomes are targeted against HER2 positive tumors. These exosomes are genetically modified to express a high affinity ligand against the HER2 receptor on their surface. The radionuclides [99mTc]Tc-HMPAO and [111In]In-oxine are loaded inside these tiny vesicles to detect tumors by the SPECT system. SPECT is a non- invasive approach for detecting tumor tissues with high sensitivity, efficient spatial resolution and quantification.

Our aim

Our aim is to develop our sensitive and clinical friendly targeted nanosized-based system to detect earlier of the most aggressive kinds of breast cancer and other HER2 positive tumors such as ovary and stomach.

1- Our product is natural. it does not stimulate the immune system compared to other synthetic counterparts.
2- radiolabeled exosomes are targeted
3. They can easily penetrate the tumor vasculature and reach deep organs by diffusing vessels in the tumor.
4- exosomes can be used as carriers.
5. Our product is equipped with clinical friendly radionuclides to detect tumors



1.MVP ready

2.successful animal study proof of concept

3.ready for optimisation of animal studies and entry into clinical Trial Phase

Our Team

Dr. Siamak Faez

Ali Faez

Mahlegha Ghavami

Mahboube Shahrabi

Dr. Mehdi ForozandeMoghadam

Contact Us

Interested in using precisionexosome’s cutting edge technology?